Teladoc Health (TDOC) EBIT (2014 - 2026)

Teladoc Health has disclosed EBIT across 13 years of filings, most recently posting -$61.8 million for Q1 2026.

• EBIT for Q1 2026 came in at -$61.8 million, up 48.79% year-over-year; the trailing twelve-month figure through Mar 2026 was -$204.1 million (up 80.64% YoY), and the FY2025 annual result was -$263.0 million, up 74.24% from the prior year.
• EBIT came in at -$61.8 million for Q1 2026 at Teladoc Health, down from -$36.0 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$35.1 million in Q4 2023 to a low of -$6.7 billion in Q1 2022.
• The 5-year median for EBIT is -$71.6 million (2023), against an average of -$896.9 million.
• Across the five-year window, EBIT slumped 9109.86% in 2022 and jumped 99.08% in 2023, its largest moves.
• Teladoc Health's EBIT stood at -$3.8 billion in 2022, then surged by 99.08% to -$35.1 million in 2023, then slumped by 37.44% to -$48.2 million in 2024, then rose by 25.34% to -$36.0 million in 2025, then tumbled by 71.59% to -$61.8 million in 2026.
• The last three EBIT figures came in at -$61.8 million (Q1 2026), -$36.0 million (Q4 2025), and -$52.0 million (Q3 2025), per Business Quant data.